XML 80 R47.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue - Additional Information (Details) - USD ($)
1 Months Ended 12 Months Ended
Feb. 28, 2019
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disaggregation Of Revenue [Line Items]        
Revenue from collaboration agreement   $ 185,308,000 $ 154,344,000 $ 98,382,000
Medicare Reimbursements        
Disaggregation Of Revenue [Line Items]        
Revenue from collaboration agreement   5,200,000 5,800,000 1,400,000
Medicare Reimbursements | Immune Medicine Service Revenue        
Disaggregation Of Revenue [Line Items]        
Revenue from collaboration agreement   700,000    
M R D Development Agreements | Maximum        
Disaggregation Of Revenue [Line Items]        
Additional milestone payment receivable   368,500,000    
Genentech Collaboration Agreement        
Disaggregation Of Revenue [Line Items]        
Revenue from collaboration agreement   62,800,000 $ 62,000,000.0 $ 52,800,000
Non-refundable upfront payments received $ 300,000,000.0 $ 300,000,000.0    
Genentech Collaboration Agreement | Maximum        
Disaggregation Of Revenue [Line Items]        
Revenue recognition expected period   9 years    
Genentech Collaboration Agreement | Maximum | Regulatory Milestones        
Disaggregation Of Revenue [Line Items]        
Expected revenue through milestone payments   $ 75,000,000.0    
Genentech Collaboration Agreement | Maximum | Development Milestones        
Disaggregation Of Revenue [Line Items]        
Expected revenue through milestone payments   300,000,000.0    
Genentech Collaboration Agreement | Maximum | Commercial Milestones        
Disaggregation Of Revenue [Line Items]        
Expected revenue through milestone payments   1,430,000,000.0    
Genentech Collaboration Agreement | Minimum        
Disaggregation Of Revenue [Line Items]        
Expected revenue through milestone payments   $ 1,800,000,000    
Revenue recognition expected period   8 years